Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food.
antiretroviral
chemometrics
food
interaction
partial least squares
principal component analysis
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
18
04
2023
received:
10
12
2022
accepted:
16
05
2023
medline:
15
9
2023
pubmed:
23
5
2023
entrez:
23
5
2023
Statut:
ppublish
Résumé
Clinically significant interactions with food occur for more than half of antiretroviral drugs. Different physiochemical properties deriving from the chemical structures of antiretroviral drugs may contribute to the variable food effect. Chemometric methods allow analysing a large number of interrelated variables concomitantly and visualizing correlations between them. We used a chemometric approach to determine the types of correlations among different features of antiretroviral drugs and food that may influence interactions. Thirty-three antiretroviral drugs were analysed: ten nucleoside reverse transcriptase inhibitors, six non-nucleoside reverse transcriptase inhibitors, five integrase strand transfer inhibitors, ten protease inhibitors, one fusion inhibitor and one HIV maturation inhibitor. Input data for the analysis were collected from already published clinical studies, chemical records and calculations. We constructed a hierarchical partial least squares (PLS) model with three response parameters: postprandial change of time to reach maximum drug concentration (ΔT PCA models explained 64.4% to 83.4% of the variance of the original parameters (average: 76.9%), whereas the PLS model had four significant components and explained 86.2% and 71.4% of the variance in the sets of predictor and response parameters, respectively. We observed 58 significant correlations between ΔT Chemometrics is a useful and valuable tool for analysing interactions between antiretroviral drugs and food.
Substances chimiques
Reverse Transcriptase Inhibitors
0
HIV Protease Inhibitors
0
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2977-2991Informations de copyright
© 2023 British Pharmacological Society.
Références
Seyler L, Lacor P, Allard SD. Current challenges in the treatment of HIV. Polish Arch Intern Med. 2018;128(10):609-616. doi:10.20452/pamw.4357
Shubber Z, Mills EJ, Nachega JB, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):1-9. doi:10.1371/journal.pmed.1002183
Chawla A, Wang C, Patton C, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183-195. doi:10.1007/s40121-018-0201-6
World Health Organization. HIV Drug Resistance Report 2019. 2019. Accessed May 26, 2023. https://www.who.int/publications/i/item/WHO-CDS-HIV-19.21
Troya J, Bascuñana J. Safety and tolerability: current challenges to antiretroviral therapy for the long-term management of HIV infection. AIDS Rev. 2016;18(3):127-137.
Zachwieja Z. Interactions Between Drugs and Food. MedPharm; 2016.
Paśko P. Food-drug interactions among the elderly: risk assessment and recommendations for patients. Encycl Biomed Gerontol. 2019;107-114. doi:10.1016/B978-0-12-801238-3.11337-6
Wiesner A, Skrońska M, Gawlik G, Marcinkowska M, Zagrodzki P, Paśko P. Interactions of antiretroviral drugs with food, beverages, dietary supplements, and alcohol-a systematic review and meta-analysis. AIDS Behav. 2023;27(5):1441-1468. doi:10.1007/s10461-022-03880-6
European Medicines Agency. ICH guideline M9 on biopharmaceutics classification system based biowaivers. 2018. Published August 6, 2018. Accessed May 26, 2023. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m9-biopharmaceutics-classification-system-based-biowaivers-step-2b-first-version_en.pdf
Gu CH, Li H, Levons J, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24(6):1118-1130. doi:10.1007/s11095-007-9236-1
Gao Y, Gesenberg C, Zheng W. Oral formulations for preclinical studies: principle, design, and development considerations. In: Qiu Y, Chen Y, Zhang GGZ, Yu L, Mantri RV, eds. Developing Solid Oral Dosage Forms. 2nd ed. Academic Press; 2017:455-495. doi:10.1016/B978-0-12-802447-8.00017-0
Omachi F, Kaneko M, Iijima R, Watanabe M, Itagaki F. Relationship between the effects of food on the pharmacokinetics of oral antineoplastic drugs and their physicochemical properties. J Pharm Heal Care Sci. 2019;5(1):26. doi:10.1186/s40780-019-0155-1
Ngaimisi E, Mugusi S, Minzi OM, et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther. 2010;88(5):676-684. doi:10.1038/clpt.2010.172
Calcagno A, Cusato J, D'Avolio A, Bonora S. Genetic polymorphisms affecting the pharmacokinetics of antiretroviral drugs. Clin Pharmacokinet. 2017;56(4):355-369. doi:10.1007/s40262-016-0456-6
Food and Drug Administration. Assessing the effects of food on drugs in INDs and NDAs-Clinical pharmacology considerations. Guidance for Industry. 2022. Accessed October 7, 2022. https://www.fda.gov/media/121313/download
Food and Drug Administration. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002. Accessed July 1, 2022. https://www.fda.gov/files/drugs/published/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf
Brereton RG, Jansen J, Lopes J, et al. Chemometrics in analytical chemistry-part I: history, experimental design and data analysis tools. Anal Bioanal Chem. 2017;409(25):5891-5899. doi:10.1007/s00216-017-0517-1
Sainani KL. Introduction to principal components analysis. PM&R. 2014;6(3):275-278. doi:10.1016/j.pmrj.2014.02.001
Abdi H, Williams LJ. Partial least squares methods: partial least squares correlation and partial least square regression. In: Reisfeld M, Mayeno A, eds. Computational Toxicology. Humana Press; 2013:549-579. doi:10.1007/978-1-62703-059-5_23
Białek A, Zagrodzki P, Tokarz A. Chemometric analysis of the interactions among different parameters describing health conditions, breast cancer risk and fatty acids profile in serum of rats supplemented with conjugated linoleic acids. Prostaglandins Leukot Essent Fatty Acids. 2016;106:1-10. doi:10.1016/j.plefa.2015.12.006
Boulesteix AL, Strimmer K. Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. Brief Bioinform. 2007;8(1):32-44. doi:10.1093/bib/bbl016
Stanimirova I, Daszykowski M, Walczak B. Methods of supervised learning-calibration, discrimination and classification. In: Zuba D, Parczewski A, eds. Chemometrics in Analytics-Selected Issues. Publishing House of the Institute of Forensic Expertise; 2008:133-191.
Frank I, Feikema J, Constantine N, Kowalski B. Prediction of product quality from spectral data using the partial least-squares method. J Chem Inf Comput Sci. 1984;24(1):20-24. doi:10.1021/ci00041a602
Singh KP, Malik A, Basant N, Saxena P. Multi-way partial least squares modeling of water quality data. Anal Chim Acta. 2007;584(2):385-396. doi:10.1016/j.aca.2006.11.038
Gottfries J, Sjögren M, Holmberg B, Rosengren L, Davidsson P, Blennow K. Proteomics for drug target discovery. Chemom Intel Lab Syst. 2004;73(1):47-53. doi:10.1016/j.chemolab.2003.11.011
Yi LZ, He J, Liang YZ, Yuan DL, Chau FT. Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS-LDA. FEBS Lett. 2006;580(30):6837-6845. doi:10.1016/j.febslet.2006.11.043
Caglayan MG, Palabiyik IM, Bor M, Onur F. Optimisation and validation of liquid chromatographic and partial least-squares-1 methods for simultaneous determination of enalapril maleate and nitrendipine in pharmaceutical preparations. Chem Pap. 2011;65(6):754-760. doi:10.2478/s11696-011-0078-2
Naes T, Baardseth P, Helgesen H, Isaksson T. Multivariate techniques in the analysis of meat quality. Meat Sci. 1996;43(Suppl. 1):135-149. doi:10.1016/0309-1740(96)00061-7
Šašić S, Ozaki Y. Short-wave near-infrared spectroscopy of biological fluids. 1. Quantitative analysis of fat, protein, and lactose in raw milk by partial least-squares regression and band assignment. Anal Chem. 2001;73(1):64-71. doi:10.1021/ac000469c
Paśko P, Prochownik E, Krośniak M, et al. Animals in iodine deficiency or sulfadimethoxine models of thyroid damage are differently affected by the consumption of brassica sprouts. Biol Trace Elem Res. 2020;193(1):204-213. doi:10.1007/s12011-019-01694-7
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):1-13. doi:10.1038/srep42717
Grisoni F, Ballabio D, Todeschini R, Consonni V. Molecular descriptors fro structure-activity applications: a hands-on approach. In: Nicolotti O, ed. Computational Toxicology. Humana Press; 2018:3-53. doi:10.1007/978-1-4939-7899-1_1
Koziolek M, Grimm M, Becker D, et al. Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the Intellicap® system. J Pharm Sci. 2015;104(9):2855-2863. doi:10.1002/jps.24274
Selzentry (Pfeizer Labs). Prescribing information. Accessed August 18, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022128s002lbl.pdf
Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy. 1999;19(8):932-942. doi:10.1592/phco.19.11.932.31568
Holdich T, Shiveley LA, Sawyer J. Pharmacokinetics of single oral doses of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers. Clin Drug Investig. 2006;26(5):279-286. doi:10.2165/00044011-200626050-00005
Damle BD, Yan JH, Behr D. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol. 2002;42(4):419-427. doi:10.1177/0091270002424008
Wang LH, Gardner P, Frick LW. Pharmacokinetics and safety of 524W91 following single oral administration of escalating doses in HIV-infected volunteers. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; 1995.
Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr. 2014;66(4):393-398. doi:10.1097/QAI.0000000000000193
Kaul S, Christofalo B, Raymond RH, Stewart MB, Macleod CM. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1998;42(9):2295-2298. doi:10.1128/AAC.42.9.2295
Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P. The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects. Clin Drug Investig. 2017;37(6):571-579. doi:10.1007/s40261-017-0512-5
Li Q, Jia L, Hu W, Dong S, Cai C. Bioequivalence evaluation of two formulations of tenofovir alafenamide tablets in healthy subjects under fasting and fed conditions. Drug Des Devel Ther. 2021;15:2551-2562. doi:10.2147/DDDT.S304108
Nazareno L, Holanzo A, Limjuco R, Passe S. The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients. Pharm Res. 1995;12(10):1462-1465. doi:10.1023/A:1016275118710
Moore KHP. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol. 1999;39(6):593-605. doi:10.1177/00912709922008209
Morse GD, Fischl MA, Shelton MJ, et al. Effect of food on the steady-state pharmacokinetics of delavirdine in patients with HIV infection. Clin Drug Investig. 2003;23(4):255-261. doi:10.2165/00044011-200323040-00005
Sustiva (Bristol-Myers Squibb Company). Prescribing information. Accessed July 20, 2021. https://www.ema.europa.eu/en/documents/product-information/sustiva-epar-product-information_en.pdf
Schöller-Gyüre M, Boffito M, Pozniak AL, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy. 2008;28(10):1215-1222. doi:10.1592/phco.28.10.1215
Viramune (Boehringer Ingelheim Pharmaceuticals, Inc.). Prescribing information. Accessed July 20, 2021. https://docs.boehringer-ingelheim.com/PrescribingInformation/PIs/Viramune/Viramune.pdf
Crauwels HM, Van Heeswijk RPG, Buelens A, Stevens M, Boven K, Hoetelmans RMW. Impact of food and different meal types on the pharmacokinetics of rilpivirine. J Clin Pharmacol. 2013;53(8):834-840. doi:10.1002/jcph.107
Mehta R, Piscitelli J, Wolstenholme A, et al. The effect of moderate- and high-fat meals on the bioavailability of dolutegravir/rilpivirine fixed-dose combination tablet. Clin Pharmacol Adv Appl. 2020;12:49-52. doi:10.2147/CPAA.S250751
Shiomi M, Matsuki S, Ikeda A, et al. Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study. J Clin Pharmacol. 2014;54(6):640-648. doi:10.1002/jcph.283
Krishna R, Rizk ML, Larson P, Schulz V, Kesisoglou F, Pop R. Single- and multiple-dose pharmacokinetics of once-daily formulations of raltegravir. Clin Pharmacol Drug Dev. 2018;7(2):196-206. doi:10.1002/cpdd.358
Bictarvy (Gilead sciences). Prescribing information. Accessed July 19, 2021. https://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf
Patel P, Ford SL, Lou Y, et al. Effect of a high-fat meal on the pharmacokinetics of the HIV integrase inhibitor cabotegravir. Clin Pharmacol Drug Dev. 2019;8(4):443-448. doi:10.1002/cpdd.620
Agenerase (Glaxo Group Ltd). Product characteristics. Accessed July 21, 2021. https://ec.europa.eu/health/documents/community-register/2000/200010203852/anx_3852_en.pdf
Reyataz (Bristol-Myers Squibb Company). Prescribing information. Accessed July 21, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021567s039,206352s004lbl.pdf
Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol. 2007;47(4):479-484. doi:10.1177/0091270006298603
Brouwers J, Tack J, Augustijns P. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. Pharm Res. 2007;24(10):1862-1869. doi:10.1007/s11095-007-9307-3
Carver PL, Fleisher D, Zhou SY, Kaul D, Kazanjian P, Cheng L. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm Res. 1999;16(5):718-724. doi:10.1023/A:1018880726035
Kaletra (Abbott). Prescribing information. Accessed July 21, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021251s046_021906s039lbl.pdf
Viracept (ViiV Healthcare Company). Prescribing information. Accessed July 21, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020778s036,020779s057,021503s018lbl.pdf
Norvir (AbbVie Inc.). Prescribing information. Accessed July 21, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020659s058_022417s010lbl.pdf
Kenyon CJ, Brown F, McClelland GR, Wilding IR. The use of pharmacoscintigraphy to elucidate food effects observed with a novel protease inhibitor (saquinavir). Pharm Res. 1998;15(3):417-422. doi:10.1023/A:1011972230829
Aptivus (Boehringer Ingelheim Pharmaceuticals, Inc.). Prescribing information. Accessed July 21, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf
Johnson M, Jewell RC, Gan J, Dumont E, Burns O, Johns BA. A phase 1 study to assess the relative bioavailability, food effect, and safety of a tablet formulation of GSK2838232, a novel HIV maturation inhibitor in healthy participants after single and repeated doses. Clin Pharmacol Drug Dev. 2020;9(8):972-977. doi:10.1002/cpdd.820
Alexander SPH, Fabbro D, Kelly E, et al. The Concise Guide to PHARMACOLOGY 2019/20: Enzymes. Br J Pharmacol. 2019;176(S1):S297-S396. doi:10.1111/bph.14752
Lázníček M, Lázníčková A. The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. J Pharm Biomed Anal. 1995;13(7):823-828. doi:10.1016/0731-7085(95)01504-E
Deschamps-Labat L, Péhourcq F, Jagou M, Bannwarth B. Relationship between lipophilicity and binding to human serum albumin of arylpropionic acid non-steroidal anti-inflammatory drugs. J Pharm Biomed Anal. 1997;16(2):223-229. doi:10.1016/S0731-7085(97)00017-4
Korchowiec J, Nalewajski RF. Group electronegativity and Fukui function studies of the substituent effects in aromatic and inorganic systems. Int J Quantum Chem. 1992;44(6):1027-1040. doi:10.1002/qua.560440607
Korchowiec J, Uchimaru T. The charge transfer Fukui function: extension of the finite-difference approach to reactive systems. J Phys Chem A. 1998;102(49):10167-10172. doi:10.1021/jp9829290
Korchowiec J. Recognition of the electrophilic and nucleophilic centers in molecules via the radical charge transfer Fukui function. Comput Chem. 2000;24(3-4):259-262. doi:10.1016/S0097-8485(99)00075-3
Lenain P, Mandado M, Mosquera RA, Bultinck P. Interplay between hydrogen-bond formation and multicenter π-electron delocalization: intermolecular hydrogen bonds. J Phys Chem A. 2008;112(42):10689-10696. doi:10.1021/jp805084n
Tolls J, Van Dijk J, Verbruggen EJM, Hermens JLM, Loeprecht B, Schüürmann G. Aqueous solubility-molecular size relationships: a mechanistic case study using C10- to C19-alkanes. J Phys Chem A. 2002;106(11):2760-2765. doi:10.1021/jp011755a
Gong Y, Haque S, Chowdhury P, et al. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. Expert Opin Drug Metab Toxicol. 2019;15(5):417-427. doi:10.1080/17425255.2019.1604685
Kiani YS, Jabeen I. Lipophilic metabolic efficiency (LipMetE) and drug efficiency indices to explore the metabolic properties of the substrates of selected cytochrome P450 isoforms. ACS Omega. 2019;5(1):179-188. doi:10.1021/acsomega.9b02344
Lewis DF, Ito Y. Human CYPs involved in drug metabolism: structures, substrates and binding affinities. Expert Opin Drug Metab Toxicol. 2010;6(6):661-674. doi:10.1517/17425251003674380
McDonnell AM, Dang CH. Basic review of the cytochrome P450 system. J Adv Pract Oncol. 2013;4(4):1-6. doi:10.6004/jadpro.2013.4.4.7
Ghanty TK, Ghosh SK. Correlation between hardness, polarizability, and size of atoms, molecules, and clusters. J Phys Chem. 1993;97(19):4951-4953. doi:10.1021/j100121a015
Zaklika J, Hładyszowski J, Ordon P, Komorowski L. From the electron density gradient to the quantitative reactivity indicators: local softness and the Fukui function. ACS Omega. 2022;7(9):7745-7758. doi:10.1021/acsomega.1c06540
Pearson RG. Chemical hardness and density functional theory. J Chem Sci. 2005;117(5):369-377. doi:10.1007/BF02708340
Sanderson RT. Chemical bonds and bonds energy. Academic Press; 1976.
Willig A, Wright L, Galvin TA. Practice paper of the Academy of Nutrition and Dietetics: nutrition intervention and human immunodeficiency virus infection. J Acad Nutr Diet. 2018;118(3):486-498. doi:10.1016/j.jand.2017.12.007
The Ontario HIV Treatment Network. Nutrition and HIV. Ontario HIV Treatment Network; 2018. Accessed April 4, 2023. https://www.ohtn.on.ca/rapid-response-nutrition-and-hiv/
Kosmiski L. Energy expenditure in HIV infection. Am J Clin Nutr. 2011;94(6):1677-1682. doi:10.3945/ajcn.111.012625
Willig AL, Overton ET. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr HIV/AIDS Rep. 2016;13(5):289-296. doi:10.1007/s11904-016-0330-z
Guzman N, Vijayan V. HIV-associated lipodystrophy. In: StatPearls. StatPearls Publishing; 2022.
Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140(2):e98-e124. doi:10.1161/CIR.0000000000000695
European AIDS Clinical Society. Guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9(2):72-81. doi:10.1111/j.1468-1293.2007.00534.x
Cowan EA, McGowan JP, Fine SM, et al. Diagnosis and Management of Acute HIV. Johns Hopkins University; 2021.
Kuhar DT, Henderson DK, Struble KA, et al. Updated US public health service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875-892. doi:10.1086/672271
Centers for Disease Control and Prevention: U.S. Public Health Service. Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV-United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(17):458. doi:10.15585/mmwr.mm6517a5
Centers for Disease Control and Prevention: U.S. Public Health Service. Preexoposure prophylaxis for the prevention of HIV infection in the United States-2021 update. 2021. Accessed April 1, 2023. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf